Heidelberg Spectralis OCT

海德堡光谱 OCT

• 批准号: 7793125
• 负责人: Roland THEODORE SMITH
• 金额: $ 17.58万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-04 至 2011-03-03
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7793125
• 关键词: Age related macular degeneration; Biomedical Engineering; Blindness; Caring; Clinical; Color; Computer software; Degenerative Disorder; Devices; Disease; Disease Progression; Drusen; Ensure; Eye; Eye Movements; Eye diseases; Faculty; Financial compensation; Fundus; Genetic; Glaucoma; Goals; Head; Image; Image Analysis; Imagery; Individual; Institutes; Life; Location; Measurement; Optical Coherence Tomography; Patient Care Management; Patients; Preventive; Public Health; Research; Research Project Grants; Resolution; Retinal; Retinal Degeneration; Retinal Diseases; Retinitis Pigmentosa; Running; Scanning; Sparrows; Specific qualifier value; Staging; Stargardt' s disease; System; Technology; United States; Universities; Work; follow-up; genetic analysis; geographic atrophy; imaging modality; improved; instrument; member; public health relevance

DESCRIPTION (provided by applicant): The goal of our application is to obtain a Heidelberg Spectralis OCT instrument for research at Columbia University's Harkness Eye Institute. The many faculty members here who are conducting research on retinal degenerative disorders rely on the latest imaging capabilities, image analysis and clinical staging to correlate with genetic analyses. The users specified on this application have all headed projects that have benefited many individuals suffering from eye diseases such as age-related macular degeneration (AMD), Stargardt disease, retinitis pigmentosa and glaucoma. Their work will aid in our understanding of these diseases and improve the treatment options that are available to patients living with these conditions. The ability of the Spectralis OCT to provide faster, higher resolution, multimodal visualization of the retinal layers can assist all of these projects while providing daily improvement in the management of patient care at the Eye Institute. Another advantage of the Spectralis system is that there is a dedicated, second eye tracking device which ensures compensation for eye movement and thus that the acquired images are exactly in register with the spectral domain optical coherence tomography (SD-OCT) scans. For example, the location of autofluorescence abnormalities can be precisely correlated with structural changes seen on SD-OCT. This capability is critical for multimodal study of retinal disease. This also enables follow-up examinations to be scanned in exactly the same location for reliable measurement of disease progression. This is not possible with the separate imaging modalities currently in use. The improved technology will be used by Dr. Smith in conjunction with the Department of Biomedical Engineering to improve their existing image analysis software, which quantifies drusen and geographic atrophy in color fundus, infrared, and autofluorescence images. Dr. Allikmets, who is examining the genetics of AMD, can use the instrument to correlate his genetic findings with the clinical stage of the disease. Similar uses will be made in Dr. Sparrow's research on Stargardt disease, Dr. Tsang's research on retinitis pigmentosa and Dr. Hood's work on glaucoma. The Eye Institute already has the capability of maintaining and running the instrument, with staff that are fully capable of using the Spectralis, and a commitment to allocate its usage fairly among all the research projects being conducted at Columbia. Public Health Relevance: Since age-related macular degeneration (AMD) is the leading cause of blindness in the United States, improvement in treatment options and preventive care resulting from improved understanding of the disease would have a large impact on public health. Research done at the Columbia University Harkness Eye Institute on AMD, as well as other eye diseases, would greatly benefit from the technology of the Spectralis, a new imaging instrument with faster image acquisition and improved retinal visualization.

描述（由申请人提供）：我们申请的目标是获得一台 Heidelberg Spectralis OCT 仪器，用于哥伦比亚大学哈克尼斯眼科研究所的研究。这里的许多从事视网膜退行性疾病研究的教员依靠最新的成像能力、图像分析和临床分期来与遗传分析相关联。该应用程序中指定的用户所领导的项目均已使许多患有眼部疾病（例如年龄相关性黄斑变性（AMD）、斯塔加特病、色素性视网膜炎和青光眼）的人受益。他们的工作将有助于我们了解这些疾病，并改善患有这些疾病的患者可用的治疗选择。 Spectralis OCT 能够提供更快、更高分辨率、多模态的视网膜层可视化，可以协助所有这些项目，同时改善眼科研究所患者护理管理的日常工作。 Spectralis 系统的另一个优点是，有一个专用的第二只眼睛跟踪设备，可确保对眼睛运动进行补偿，从而确保获取的图像与谱域光学相干断层扫描 (SD-OCT) 扫描精确对准。例如，自发荧光异常的位置可以与 SD-OCT 上看到的结构变化精确相关。这种能力对于视网膜疾病的多模式研究至关重要。这也使得后续检查能够在完全相同的位置进行扫描，以可靠地测量疾病进展。对于目前使用的单独成像模式来说这是不可能的。 史密斯博士将与生物医学工程系一起使用改进的技术来改进他们现有的图像分析软件，该软件可以量化彩色眼底、红外和自发荧光图像中的玻璃疣和地理萎缩。 Allikmets 博士正在检查 AMD 的遗传学，他可以使用该仪器将他的遗传学发现与该疾病的临床阶段相关联。 Sparrow 博士对 Stargardt 病的研究、Tsang 博士对视网膜色素变性的研究以及 Hood 博士对青光眼的研究也将有类似的用途。眼科研究所已经具备维护和运行该仪器的能力，其工作人员完全有能力使用 Spectralis，并承诺在哥伦比亚正在进行的所有研究项目中公平分配其使用。 公共健康相关性：由于年龄相关性黄斑变性 (AMD) 是美国失明的主要原因，因此通过提高对该疾病的了解而改进治疗方案和预防保健将对公共健康产生重大影响。哥伦比亚大学哈克尼斯眼科研究所针对 AMD 以及其他眼部疾病所做的研究将极大受益于 Spectralis 的技术，Spectralis 是一种新型成像仪器，具有更快的图像采集速度和改进的视网膜可视化功能。